A Phase I/Ib Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT)
Matthew S. Davids(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Frederick L. Locke(Moffitt Cancer Center), Corey Cutler(Harvard University), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Vincent T. Ho(Dana-Farber Cancer Institute), Asad Bashey, Haesook T. Kim(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Pavan Bachireddy(Broad Institute), Michael Mazzeo(Harvard University), Robert J. Soiffer(Dana-Farber Cancer Institute), Edwin P. Alyea(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Caitlin Costello(University of California San Diego), Howard Streicher(National Cancer Institute), Edward D. Ball(Sheba Medical Center), Sarah Nikiforow(Otsuka (Japan)), Alexandra Savell(Dana-Farber Cancer Institute), Rodrigo Maegawa(Eastern Maine Medical Center)
Cited by 13
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k